Our identification of Rapamycin-induced miRNA reveals a novel and complex signaling network downstream of mTOR with potential therapeutic implications for women with LAM and patients with TSC receiving Rapamycin therapy. This evidence concerns the gene TSC1 and lymphangioleiomyomatosis.